p53 is a common denominator among human cancers. How was it discovered? What are the persistent questions about its function? Aa Aa Aa It seems nearly impossible for a normal cell to become a ...

Discover recent research that sheds light on a promising therapeutic strategy for tackling prostate cancer by targeting the ...

The new drug application of glecirasib is currently under evaluation by the Center for Drug Evaluation of the National Medical Products Administration of China, and has been granted Priority Review ...

our novel dual KRAS G12C inhibitor, and move our second development candidate, FMC-220, a first-in-class covalent p53 Y220C activator, closer to the clinic,” said Chris Varma, Ph.D., chairman ...

IND anticipated in 2H 2025 Frontier’s pipeline of precision medicines continues to progress rapidly, with interim clinical data for FMC-376, an ON+OFF KRASG12C inhibitor currently in the Phase 1 ...